Jump to content
Fantasy Football - Footballguys Forums

***OFFICIAL CYDY/Leronlimab Thread***


Recommended Posts

  • Replies 11.2k
  • Created
  • Last Reply

Top Posters In This Topic

Top Posters In This Topic

Popular Posts

Yes, go ahead FC42

I closed.  Cydy operation mountain house completed.

Fear is a disease.  Get rid of it or you're doomed for failure.  Though I did hear Leronlimab cures it. This is NOT an investment.  It is a Grand Slam Home Run or a Strike Out gamble in the stock

8 minutes ago, ChiefD said:

I'm getting close to being green also. Not sure what I'm going to do. Chet's comment the other day makes me want to hold for awhile. 

Good luck to you guys. I don’t have the stomach anymore for stuff like this. I got rid of 90% of mine at the peaks in July and September. Amazed that you guys held out through the vaccines and everything. No idea if you should hold, but as an FYI, my IRA which is where I had most of my CYDY is up about 50% from those two sales so it’s like I sold today at almost $10 and $8. I’d just be cautious based on the rest of your portfolio and if there’s other things you’d like to own more. Otherwise, good luck! Hope you get back to $10. I think I made myself feel better by figuring out how much extra CYDY got me after reinvesting the profits. Thanks again Chet.

  • Thanks 1
Link to post
Share on other sites

I've got a decent amount accumulated.  This gameplan could change but right now I'm thinking of selling 1/3 of it somewhere around 1/15/21, well before any decisions about EUA or approval are made.

Im up big on CYDY at this point and can freeroll with everything I have right now but think I should still bank more of the profit before any approval decisions.  I was able to get in early enough and make money the first time around, was actually able to get most of it out in the high 7s, the day that it had a big drop.

I always held a small amount but basically started over again and my average cost per share on this run is around $2.40

  • Like 1
Link to post
Share on other sites

WSJ article as well

Quote

CytoDyn, a biotechnology company, recently applied to the FDA to test its experimental drug, leronlimab, on 102 long Covid patients.
PHOTO: CYTODYN INC.

Doctors have previously used some existing drugs to alleviate specific symptoms of long Covid in a piecemeal fashion. What’s different now is that scientists are testing drugs intended to treat the underlying causes of the condition.

CytoDyn, a Vancouver, Wash., biotechnology company, recently applied to the U.S. Food and Drug Administration to test its experimental drug, leronlimab, on 102 long Covid patients, says Scott A. Kelly, chief medical officer of the company.

Leronlimab, a monoclonal antibody administered through subcutaneous injections, was developed as an HIV drug. When the pandemic hit, the company shifted to Covid-19. The same receptor that allows HIV to enter cells is also important in regulating immune cells; some doctors believe long-term Covid symptoms are caused by the immune system going haywire. The company has recently tested the treatment in severe Covid patients as well as in mild to moderate cases, some of which were long-haul patients.

Some patients with long-term symptoms reported their brain fog and cognition issues improving after treatment. “When we started to see these patients saying the brain fog was clearing, we were encouraged,” says Dr. Kelly. A new trial would test the drug specifically on long-haul patients.

Dr. Kelly says they believe leronlimab may be alleviating brain inflammation. Leronlimab binds to a cell receptor that contributes to the regulation of immune cells that sometimes flood an area and destroy tissue. Blocking that receptor may slow down the inflammatory response, which some scientists believe is triggering problems in long Covid patients.

“We are hopeful we can control the neuroinflammation in the brain which we think causes a lot of these problems with autonomic dysfunction, fatigue, brain fog,” says Dr. Kelly. The company says patients haven’t reported significant side effects in the clinical trials they’ve done for Covid and HIV.

Dr. Kelly says the interest in such a treatment is tremendous. “I get emails every day about wanting to participate in the trial,” he says.

 Link (need subscription)

Edited by Dave RL
Add article
  • Like 2
  • Thanks 1
Link to post
Share on other sites

Whatever happened with the Nasdaq uplisting?  I kind of forgot about that once it dropped to sub $4.  Is that back on the table now?  Would expect a big pop if that happened?  Where would the price go once its "legit"

Edited by unckeyherb
Link to post
Share on other sites
4 minutes ago, unckeyherb said:

Whatever happened with the Nasdaq uplisting?  I kind of forgot about that once it dropped to sub $4.  Is that back on the table now?  Would expect a big pop if that happened?  Where would the price go once its "legit"

To the moon Alice.

  • Like 2
Link to post
Share on other sites
29 minutes ago, unckeyherb said:

Whatever happened with the Nasdaq uplisting?  I kind of forgot about that once it dropped to sub $4.  Is that back on the table now?  Would expect a big pop if that happened?  Where would the price go once its "legit"

They mentioned it on the last call... I think I remember they're still a ways away due to other factors (cash on hand? assets?). Stock price helps, approval would help, but still not there yet.

Link to post
Share on other sites
4 minutes ago, Don Hutson said:

Looks like CFO Michael Mulholland sold 32,000 shares on 12/17, 487,002 shares on 12/18. and 589,797 shares today.  He now owns 284,081 shares.  In other words, he sold 75% of his shares.

https://www.sec.gov/Archives/edgar/data/1175680/000180709420000029/xslF345X03/primary_doc.xml

Well that may stop the momentum 

Link to post
Share on other sites
12 minutes ago, Don Hutson said:

Looks like CFO Michael Mulholland sold 32,000 shares on 12/17, 487,002 shares on 12/18. and 589,797 shares today.  He now owns 284,081 shares.  In other words, he sold 75% of his shares.

https://www.sec.gov/Archives/edgar/data/1175680/000180709420000029/xslF345X03/primary_doc.xml

Looks like part of a pre determined plan sale executed 11/12.  Bunch of NQ’s, non-qualified stock options.  The spread between the exercise price and grant price is taxable compensation (ordinary income) to him.  Pretty common from lots of exec’s I have seen.  Most NQ’s I see are same day exercise and sell due to tax consequences.

Imagine he has many more ‘in the money’ options.

 

Link to post
Share on other sites
1 minute ago, Taxguy said:

Looks like part of a pre determined plan sale executed 11/12.  Bunch of NQ’s, non-qualified stock options.  The spread between the exercise price and grant price is taxable compensation (ordinary income) to him.  Pretty common from lots of exec’s I have seen.  Most NQ’s I see are same day exercise and sell due to tax consequences.

Imagine he has many more ‘in the money’ options.

 

We'll see a drop tomorrow.

The market sucking up 1mm shares on up days is good though.

Link to post
Share on other sites

 

11 minutes ago, Capella said:

I don’t think the buying public knows or generally cares about this sort of thing. Does make you wonder why the hell he would do it though. 

Its not like they were going to expire anytime soon, definitely didn't need to put this in motion now.  If he was confident that this had a lot more room to run, seems odd to sell now.

I hate thinking about this stuff when you don't know the entire situation/motivation but its not good.

Link to post
Share on other sites
5 minutes ago, chet said:

They received EIND approval from the FDA. I think this is a precursor to a broader approval in Jan. I think it’s positive but the stock has gone up so much recently that I’m not sure how it will react today. 

https://ir.stockpr.com/cytodyn/news/detail/492

 

Very nice.  Agree completely with your assessment!

Link to post
Share on other sites
10 hours ago, Taxguy said:

Looks like part of a pre determined plan sale executed 11/12.  Bunch of NQ’s, non-qualified stock options.  The spread between the exercise price and grant price is taxable compensation (ordinary income) to him.  Pretty common from lots of exec’s I have seen.  Most NQ’s I see are same day exercise and sell due to tax consequences.

Imagine he has many more ‘in the money’ options.

 

User name checks out

  • Like 2
  • Thanks 1
Link to post
Share on other sites
16 minutes ago, Capella said:

Knowing a EAU is a bigger deal, what is the difference between an EIND and a EAU?

I believe EIND patients have to be approved separately and that EUA patients can be treated simply with the doctor’s approval. 
 

At any rate, EUA is broader and makes the drug more accessible. 

  • Thanks 1
Link to post
Share on other sites
20 minutes ago, Capella said:

Knowing a EAU is a bigger deal, what is the difference between an EIND and a EAU?

Eind is go ahead and administer the patient is ####ed anyway. 

Eua is this drug worked in a study better than anything else available and there is an emergency need

plus what Chet said

Edited by BassNBrew
  • Thanks 1
Link to post
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.


×
×
  • Create New...